激肽釋放酶原(PK)多克隆抗體
Polyclonal Antibody to Prekallikrein (PK)
KLKB1; KLK3; Fletcher Factor; Kallikrein B,Plasma; Kininogenin; Plasma prekallikrein
- 編號PAB801Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPB801Hu01-激肽釋放酶原(PK)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術,請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 598 ¥ 1394 ¥ 1992 ¥ 4980 ¥ 19920
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對PK的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別PK。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質期內,在適當?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務
相關產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應用(僅供研究使用,不用于臨床診斷!) |
RPB801Hu01 | 激肽釋放酶原(PK)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB801Hu01 | 激肽釋放酶原(PK)多克隆抗體 | WB; IHC; ICC; IP. |
MAB801Hu22 | 激肽釋放酶原(PK)單克隆抗體 | WB; IHC; ICC; IP. |
SEB801Hu | 激肽釋放酶原(PK)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB801Hu | 激肽釋放酶原(PK)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Int J Immunopathol Pharmacol | Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes [PubMed: 25964383] |
Thromb Res | Factor XII–mediated contact activation related to poor prognosis in disseminated intravascular coagulation [PubMed: 26706311] |
Thrombosis Research | Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coaCavia (Guinea pig )lation [Pubmed:26706311] |
Annals of Laboratory Medicine | The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c. 1198G> T) [Pubmed: 30430790] |
J Cell Mol Med | Huaier shows anti?\cancer activities by inhibition of cell growth, migration and energy metabolism in lung cancer through PI3K/AKT/HIF?\1|á pathway [33377619] |
J Thromb Thrombolysis | Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors [Pubmed:34993714] |
留言咨詢